A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials
Identifieur interne : 001846 ( Main/Exploration ); précédent : 001845; suivant : 001847A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials
Auteurs : Anthony E. Lang [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-04.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Autonomic Nervous System Diseases (etiology), Behavior, Behavioral Symptoms (etiology), Clinical Trials as Topic, Cognition Disorders (etiology), Diagnosis, Disease Progression, Early Diagnosis, Humans, Medical screening, Nervous system diseases, Olfaction, Parkinson Disease (complications), Parkinson Disease (diagnosis), Parkinson Disease (therapy), Parkinson disease, Parkinson's disease, Predictive Value of Tests, Rapid eye movement, Sensitivity and Specificity, Sleep Disorders (etiology), neuroprotection, non‐motor, olfaction, premotor, rapid eye movement behavior disorder, screening.
- MESH :
- complications : Parkinson Disease.
- diagnosis : Parkinson Disease.
- etiology : Autonomic Nervous System Diseases, Behavioral Symptoms, Cognition Disorders, Sleep Disorders.
- therapy : Parkinson Disease.
- Clinical Trials as Topic, Disease Progression, Early Diagnosis, Humans, Predictive Value of Tests, Sensitivity and Specificity.
Abstract
The neurodegenerative process is well established in Parkinson patients presenting to a physician with early motor signs. There is increasing evidence that a variety of nonmotor features can antedate the typical presentation by many years. As the search for successful disease‐modifying treatment advances, it is logical to consider how this could be applied to patients in the earliest stages of the disease, indeed before motor features develop, with the obvious goal of delaying and even preventing the onset of the motor syndrome. However, many of these nonmotor symptoms are rather nonspecific and are not uncommon in the general population. Being able to identify individuals in whom these features are more likely to represent true premotor Parkinson's disease represents a major challenge. Until widely applicable and reliable biomarkers for the presence of Parkinson's disease‐related pathology are developed (including biomarkers of disease severity and rate of progression), further evaluation of possible premotor features in selected populations will probably serve as the basis for future studies of disease‐modifying therapies. This article will review the current status of premotor symptoms of Parkinson's disease and discuss their potential for early diagnosis and the design of neuroprotective trials. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23609
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000680
- to stream Istex, to step Curation: 000680
- to stream Istex, to step Checkpoint: 000579
- to stream PubMed, to step Corpus: 001300
- to stream PubMed, to step Curation: 001300
- to stream PubMed, to step Checkpoint: 001510
- to stream Ncbi, to step Merge: 003127
- to stream Ncbi, to step Curation: 003127
- to stream Ncbi, to step Checkpoint: 003127
- to stream Main, to step Merge: 001900
- to stream PascalFrancis, to step Corpus: 000614
- to stream PascalFrancis, to step Curation: 002704
- to stream PascalFrancis, to step Checkpoint: 000743
- to stream Main, to step Merge: 001D33
- to stream Main, to step Curation: 001846
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CDC20C8FA71C31FB26A791869404C47896887B38</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23609</idno>
<idno type="url">https://api.istex.fr/document/CDC20C8FA71C31FB26A791869404C47896887B38/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000680</idno>
<idno type="wicri:Area/Istex/Curation">000680</idno>
<idno type="wicri:Area/Istex/Checkpoint">000579</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Lang A:a:critical:appraisal</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21484865</idno>
<idno type="wicri:Area/PubMed/Corpus">001300</idno>
<idno type="wicri:Area/PubMed/Curation">001300</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001510</idno>
<idno type="wicri:Area/Ncbi/Merge">003127</idno>
<idno type="wicri:Area/Ncbi/Curation">003127</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003127</idno>
<idno type="wicri:Area/Main/Merge">001900</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0228423</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000614</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002704</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000743</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Lang A:a:critical:appraisal</idno>
<idno type="wicri:Area/Main/Merge">001D33</idno>
<idno type="wicri:Area/Main/Curation">001846</idno>
<idno type="wicri:Area/Main/Exploration">001846</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials</title>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-04">2011-04</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="775">775</biblScope>
<biblScope unit="page" to="783">783</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CDC20C8FA71C31FB26A791869404C47896887B38</idno>
<idno type="DOI">10.1002/mds.23609</idno>
<idno type="ArticleID">MDS23609</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Autonomic Nervous System Diseases (etiology)</term>
<term>Behavior</term>
<term>Behavioral Symptoms (etiology)</term>
<term>Clinical Trials as Topic</term>
<term>Cognition Disorders (etiology)</term>
<term>Diagnosis</term>
<term>Disease Progression</term>
<term>Early Diagnosis</term>
<term>Humans</term>
<term>Medical screening</term>
<term>Nervous system diseases</term>
<term>Olfaction</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Predictive Value of Tests</term>
<term>Rapid eye movement</term>
<term>Sensitivity and Specificity</term>
<term>Sleep Disorders (etiology)</term>
<term>neuroprotection</term>
<term>non‐motor</term>
<term>olfaction</term>
<term>premotor</term>
<term>rapid eye movement behavior disorder</term>
<term>screening</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Autonomic Nervous System Diseases</term>
<term>Behavioral Symptoms</term>
<term>Cognition Disorders</term>
<term>Sleep Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Disease Progression</term>
<term>Early Diagnosis</term>
<term>Humans</term>
<term>Predictive Value of Tests</term>
<term>Sensitivity and Specificity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Comportement</term>
<term>Diagnostic</term>
<term>Dépistage</term>
<term>Maladie de Parkinson</term>
<term>Mouvement oculaire rapide</term>
<term>Olfaction</term>
<term>Pathologie du système nerveux</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The neurodegenerative process is well established in Parkinson patients presenting to a physician with early motor signs. There is increasing evidence that a variety of nonmotor features can antedate the typical presentation by many years. As the search for successful disease‐modifying treatment advances, it is logical to consider how this could be applied to patients in the earliest stages of the disease, indeed before motor features develop, with the obvious goal of delaying and even preventing the onset of the motor syndrome. However, many of these nonmotor symptoms are rather nonspecific and are not uncommon in the general population. Being able to identify individuals in whom these features are more likely to represent true premotor Parkinson's disease represents a major challenge. Until widely applicable and reliable biomarkers for the presence of Parkinson's disease‐related pathology are developed (including biomarkers of disease severity and rate of progression), further evaluation of possible premotor features in selected populations will probably serve as the basis for future studies of disease‐modifying therapies. This article will review the current status of premotor symptoms of Parkinson's disease and discuss their potential for early diagnosis and the design of neuroprotective trials. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Ontario"><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001846 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001846 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:CDC20C8FA71C31FB26A791869404C47896887B38 |texte= A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials }}
This area was generated with Dilib version V0.6.23. |